Casein kinase 2 regulates both apoptosis and the cell cycle following DNA damage induced by 6-thioguanine

Clinical Cancer Research

Volumn 11, Issue 6, 2005, Pages 2355-2363

  Yamane, Kazuhiko ^a   Kinsella, Timothy J ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; ALANINE; APIGENIN; CASEIN KINASE II; CASPASE INHIBITOR; EMODIN; ISOENZYME; PHOSPHOTRANSFERASE INHIBITOR; SERINE; SMALL INTERFERING RNA; TIOGUANINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; COLON ADENOCARCINOMA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA DAMAGE; ENDOPLASMIC RETICULUM; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MISMATCH REPAIR; MUTATION; PRIORITY JOURNAL; REPRESSOR GENE; TUMOR CELL; UTERINE CERVIX CARCINOMA;

APOPTOSIS; CASEIN KINASE II; CASPASES; CELL CYCLE; DNA DAMAGE; DNA REPAIR; ENDOPLASMIC RETICULUM; ENZYME INHIBITORS; HELA CELLS; HUMANS; RNA, SMALL INTERFERING; THIOGUANINE; TRANSFECTION;

EID: 16844376643     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1734     Document Type: Article

References (40)

1. Litchfield DW. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 2003;369:1-15.
2. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J 2003;17:349-68.
3. 2-M in Saccharomyces cerevisiae. J Biol Chem 1995;270:25905-14.
4. Xu X, Toselli PA, Russell LD, Seldin DC. Globozoospermia in mice lacking the casein kinase II α′ catalytic subunit. Nat Genet 1999;23:118-21.
5. Buchou T, Vernet M, Blond O, et al. Disruption of the regulatory β subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol Cell Biol 2003;23:908-15.
6. Guerra B, Issinger OG, Wang JY. Modulation of human checkpoint kinase Chk1 by the regulatory β-subunit of protein kinase CK2. Oncogene 2003;22:4933-42.
7. Desagher S, Osen-Sand A, Montessuit S, et al. Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. Mol Cell 2001;8:601-11.
8. Bohon J, de los Santos CR. Structural effect of the anticancer agent 6-thioguanine on duplex DNA. Nucleic Acids Res 2003;31:1331-8.
9. Elgemeie GH. Thioguanine, mercaptopurine: their analogs and nucleosides as antimetabolites. Curr Pharm Des 2003;9:2627-42.
10. Christie NT, Drake S, Meyn RE, Nelson JA. 6-Thioguanine-induced DNA damage as a determinant of cytotoxicity in cultured Chinese hamster ovary cells. Cancer Res 1984;44:3665-71.
11. Pan BF, Nelson JA. Characterization of the DNA damage in 6-thioguanine-treated cells. Biochem Pharmacol 1990;40:1063-9.
12. Fairchild CR, Maybaum J, Kennedy KA. Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment. Biochem Pharmacol 1986;35:3533-41.
13. Pan BF, Priebe TS, Nelson JA. Mechanisms of resistance to 6-thioguanine in a murine pancreatic tumor. Cancer Chemother Pharmacol 1992;29:471-4.
14. Ling YH, Chan JY, Beattie KL, Nelson JA. Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase, and endonuclease reactions. Mol Pharmacol 1992;42:802-7.
15. Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996;273:1109-11.
16. 2/M arrest in MMR-proficient RKO cells. Clin Cancer Res 2003;9:2327-34.
17. 2-M arrest by 6-thioguanine involves the ATR-Chk1 pathway. Biochem Biophys Res Commun 2004;318:297-302.
18. Yan T, Desai AB, Jacobberger JW, Sramkoski RL, Loh T, Kinsella TJ. CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses. Mol Cancer Ther 2004;3:1-11.
19. 2 arrest responses without altering survival after ionizing radiation. Cancer Res 2001;61:8290-7.
20. Krynetskaia NF, Brenner TL, Krynetski EY, et al. Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in msh2-/- mice. Mol Pharmacol 2003;64:456-65.
21. Meek DW, Simon S, Kikkawa U, Eckhart W. The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II. EMBO J 1990;9:3253-60.
22. 1 phase of the HeLa cell division cycle. J Biol Chem 1992;267:20317-25.
23. O'Brien KA, Lemke SJ, Cocke KS, Rao RN, Beckmann RP. Casein kinase 2 binds to and phosphorylates BRCA1. Biochem Biophys Res Commun 1999;260:658-64.
24. 2-M cell cycle checkpoint. Cancer Res 2003;63:3049-53.
25. Lorenz P, Pepperkok R, Ansorge W, Pyerin W. Cell biological studies with monoclonal and polyclonal antibodies against human casein kinase II subunit β demonstrate participation of the kinase in mitogenic signaling. J Biol Chem 1993;268:2733-9.
26. 1/S phases of the cell cycle. J Biol Chem 1994;269:6986-91.
27. Rethinaswamy A, Birnbaum MJ, Glover CV. Temperature-sensitive mutations of the CKA1 gene reveal a role for casein kinase II in maintenance of cell polarity in Saccharomyces cerevisiae. J Biol Chem 1998;273:5869-77.
28. Marra G, Chang CL, Laghi LA, Chauhan DP, Young D, Boland CR. Expression of human MutS homolog 2 (hMSH2) protein in resting and proliferating cells. Oncogene 1996;13:21899-6.
29. Koi M, Umar A, Chauhan DP, et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-TV-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 1994;54:4308-12.
30. Jacob S, Aguado M, Fallik D, Praz F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 2001;61:6555-62.
31. Thomenius MJ, Wang NS, Reineks EZ, Wang Z, Distelhorst CW. Bcl-2 on the endoplasmic reticulum regulates Bax activity by binding to BH3-only proteins. J Biol Chem 2003;278:6243-50.
32. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002;3:737-47.
33. Channavajhala P, Seldin DC. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene 2002;21:5280-8.
34. Izeradjene K, Douglas L, Delaney A, Houghton JA. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human Rhabdomyosarcoma cells. Clin Cancer Res 2004;10:6650-60.
35. de Wind N, Dekker M, Berns A, Radman M, te Riele H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 1995;82:321-30.
36. Umar A, Koi M, Risinger JI, et al. Correction of hypermutability, N-methyl-N′-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res 1997;57:3949-55.
37. Rogakou EP, Boon C, Redon C, Bonner WM. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 1999;146:905-16.
38. Li PF, Li J, Muller EC, Otto A, Dietz R, von Harsdorf R. Phosphorylation by protein kinase CK2: a signaling switch for the caspase-inhibiting protein ARC. Mol Cell 2002;10:247-58.
39. De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH. Crystal structure of cyclin-dependent kinase 2. Nature 1993;363:595-602.
40. Toczyski DP, Galgoczy DJ, Hartwell LH. CDC5 and CKII control adaptation to the yeast DNA damage checkpoint. Cell 1997;90:1097-106.